CA2974091A1 - Intravenous baclofen formulations and treatment methods - Google Patents

Intravenous baclofen formulations and treatment methods Download PDF

Info

Publication number
CA2974091A1
CA2974091A1 CA2974091A CA2974091A CA2974091A1 CA 2974091 A1 CA2974091 A1 CA 2974091A1 CA 2974091 A CA2974091 A CA 2974091A CA 2974091 A CA2974091 A CA 2974091A CA 2974091 A1 CA2974091 A1 CA 2974091A1
Authority
CA
Canada
Prior art keywords
baclofen
oral
solution
administration
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2974091A
Other languages
English (en)
French (fr)
Inventor
Jim Cloyd
Adolfo GOMEZ
Linda Krach
Robert Kriel
John Schrogie
Stephen Tucker
Rob Tuohy
Original Assignee
Allaysis LLC
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allaysis LLC, University of Minnesota System filed Critical Allaysis LLC
Publication of CA2974091A1 publication Critical patent/CA2974091A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2974091A 2015-01-15 2016-01-15 Intravenous baclofen formulations and treatment methods Abandoned CA2974091A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562103902P 2015-01-15 2015-01-15
US62/103,902 2015-01-15
PCT/US2016/013672 WO2016115504A1 (en) 2015-01-15 2016-01-15 Intravenous baclofen formulations and treatment methods

Publications (1)

Publication Number Publication Date
CA2974091A1 true CA2974091A1 (en) 2016-07-21

Family

ID=56406482

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2974091A Abandoned CA2974091A1 (en) 2015-01-15 2016-01-15 Intravenous baclofen formulations and treatment methods

Country Status (6)

Country Link
US (5) US10350183B2 (https=)
EP (1) EP3244884A4 (https=)
JP (1) JP2018502924A (https=)
CA (1) CA2974091A1 (https=)
MX (1) MX2017009313A (https=)
WO (1) WO2016115504A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350183B2 (en) 2015-01-15 2019-07-16 Allaysis, Llc Intravenous baclofen formulations and treatment methods
MX2018004656A (es) * 2015-10-21 2019-01-10 Allaysis Llc Baclofeno intravenoso y metodos de tratamiento.
US20230190570A1 (en) * 2020-06-22 2023-06-22 Otivio As Methods for treating spasticity using anti-spasmodic compositions and negative pressure therapy
EP4019016A1 (en) * 2020-12-24 2022-06-29 Allaysis, LLC Methods of administering intravenous baclofen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH26730A (en) 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
DK0461958T3 (da) 1990-06-15 1995-02-20 Synthelabo 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxanderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i terapien
IT1319275B1 (it) * 1999-10-08 2003-09-26 Neuroscienze S C A R L Uso del baclofen nel trattamento dell'astinenza da etanolo.
US6969383B2 (en) 2002-09-27 2005-11-29 Medtronic, Inc. Method for treating severe tinnitus
WO2005037215A2 (en) * 2003-10-14 2005-04-28 Massachusetts Institute Of Technology Compositions and methods for enhancing cognitive function and synaptic plasticity
US7824697B2 (en) * 2004-07-12 2010-11-02 Board Of Regents, The University Of Texas System High concentration baclofen preparations
ES2610508T3 (es) * 2006-11-22 2017-04-27 Clinical Research Associates, Llc Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
US9180108B2 (en) * 2011-10-27 2015-11-10 Medtronic, Inc. Baclofen formulations and methods for making same
WO2013180796A1 (en) * 2012-06-01 2013-12-05 Lynn Health Science Institute, Inc. Methods for treating insomnia
US10350183B2 (en) 2015-01-15 2019-07-16 Allaysis, Llc Intravenous baclofen formulations and treatment methods

Also Published As

Publication number Publication date
WO2016115504A1 (en) 2016-07-21
US20230248679A1 (en) 2023-08-10
US10933042B2 (en) 2021-03-02
EP3244884A1 (en) 2017-11-22
EP3244884A4 (en) 2018-07-25
JP2018502924A (ja) 2018-02-01
US20190388373A1 (en) 2019-12-26
US20160213631A1 (en) 2016-07-28
MX2017009313A (es) 2018-02-09
US12295929B2 (en) 2025-05-13
US20200038353A1 (en) 2020-02-06
US10350183B2 (en) 2019-07-16
US20210228520A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
US12295929B2 (en) Intravenous baclofen formulations and treatment methods
JP2013505983A5 (https=)
RU2012117563A (ru) Режим дозирования модулятора рецептора s1p
Naritoku et al. Intravenous loading of valproate for epilepsy
EP4547218A1 (en) Tirzepatide compositions and use
AU2016269337B2 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
AU2018388417B2 (en) Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes
EP4192473B1 (en) Methods of treatment using furosemide
US20200179373A1 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
US11672863B2 (en) Enhanced solubility drug-containing formulations
US20170112789A1 (en) Intravenous baclofen and methods of treatment
US11241424B2 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
US20200030318A1 (en) Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
JP2018531271A6 (ja) 静脈内バクロフェン及び治療方法
Aguirre et al. REPORTS OF ORIGINAL INVESTIGATIONS
KR20150027160A (ko) 척추 투여용 과포화 아세타미노펜 주사 용액

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220406